104 related articles for article (PubMed ID: 11380453)
1. High concentrations of coagulation factor VIII and thrombosis: Is the factor VIII-binding domain of von Willebrand factor implicated?
Bowen DJ; MacLean RM; Pellard S; Collins PW
Br J Haematol; 2001 Jun; 113(3):655-7. PubMed ID: 11380453
[TBL] [Abstract][Full Text] [Related]
2. High levels of coagulation factors and venous thrombosis risk: strongest association for factor VIII and von Willebrand factor.
Rietveld IM; Lijfering WM; le Cessie S; Bos MHA; Rosendaal FR; Reitsma PH; Cannegieter SC
J Thromb Haemost; 2019 Jan; 17(1):99-109. PubMed ID: 30471183
[TBL] [Abstract][Full Text] [Related]
3. Von Willebrand factor drives the association between elevated factor VIII and poor outcomes in patients with ischemic stroke.
Samai A; Monlezun D; Shaban A; George A; Dowell L; Kruse-Jarres R; Schluter L; El Khoury R; Martin-Schild S
Stroke; 2014 Sep; 45(9):2789-91. PubMed ID: 25028444
[TBL] [Abstract][Full Text] [Related]
4. A genetic association study of circulating coagulation factor VIII and von Willebrand factor levels.
de Vries PS; Reventun P; Brown MR; Heath AS; Huffman JE; Le NQ; Bebo A; Brody JA; Temprano-Sagrera G; Raffield LM; Ozel AB; Thibord F; Jain D; Lewis JP; Rodriguez BAT; Pankratz N; Taylor KD; Polasek O; Chen MH; Yanek LR; Carrasquilla GD; Marioni RE; Kleber ME; Trégouët DA; Yao J; Li-Gao R; Joshi PK; Trompet S; Martinez-Perez A; Ghanbari M; Howard TE; Reiner AP; Arvanitis M; Ryan KA; Bartz TM; Rudan I; Faraday N; Linneberg A; Ekunwe L; Davies G; Delgado GE; Suchon P; Guo X; Rosendaal FR; Klaric L; Noordam R; van Rooij F; Curran JE; Wheeler MM; Osburn WO; O'Connell JR; Boerwinkle E; Beswick A; Psaty BM; Kolcic I; Souto JC; Becker LC; Hansen T; Doyle MF; Harris SE; Moissl AP; Deleuze JF; Rich SS; van Hylckama Vlieg A; Campbell H; Stott DJ; Soria JM; de Maat MPM; Almasy L; Brody LC; Auer PL; Mitchell BD; Ben-Shlomo Y; Fornage M; Hayward C; Mathias RA; Kilpeläinen TO; Lange LA; Cox SR; März W; Morange PE; Rotter JI; Mook-Kanamori DO; Wilson JF; van der Harst P; Jukema JW; Ikram MA; Blangero J; Kooperberg C; Desch KC; Johnson AD; Sabater-Lleal M; Lowenstein CJ; Smith NL; Morrison AC
Blood; 2024 May; 143(18):1845-1855. PubMed ID: 38320121
[TBL] [Abstract][Full Text] [Related]
5. Type 2N von Willebrand disease: rapid genetic diagnosis of G2811A (R854Q), C2696T (R816W), T2701A (H817Q) and G2823T (C858F)--detection of a novel candidate type 2N mutation: C2810T (R854W).
Bowen DJ; Standen GR; Mazurier C; Gaucher C; Cumming A; Keeney S; Bidwell J
Thromb Haemost; 1998 Jul; 80(1):32-6. PubMed ID: 9684781
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms and mutations in vWF and ADAMTS13 genes and their correlation with plasma levels of FVIII and vWF in patients with deep venous thrombosis.
Bittar LF; de Paula EV; Mello TB; Siqueira LH; Orsi FL; Annichino-Bizzacchi JM
Clin Appl Thromb Hemost; 2011 Oct; 17(5):514-8. PubMed ID: 20682599
[TBL] [Abstract][Full Text] [Related]
7. Expression of two type 2N von Willebrand disease mutations identified in exon 18 of von Willebrand factor gene.
Hilbert L; Jorieux S; Fontenay-Roupie M; Guicheteau M; Fressinaud E; Meyer D; Mazurier C;
Br J Haematol; 2004 Oct; 127(2):184-9. PubMed ID: 15461624
[TBL] [Abstract][Full Text] [Related]
8. Molecular genetics of von Willebrand disease.
Mazurier C; Ribba AS; Gaucher C; Meyer D
Ann Genet; 1998; 41(1):34-43. PubMed ID: 9599650
[TBL] [Abstract][Full Text] [Related]
9. High factor VIII antigen levels increase the risk of venous thrombosis but are not associated with polymorphisms in the von Willebrand factor and factor VIII gene.
Kamphuisen PW; Eikenboom JC; Rosendaal FR; Koster T; Blann AD; Vos HL; Bertina RM
Br J Haematol; 2001 Oct; 115(1):156-8. PubMed ID: 11722428
[TBL] [Abstract][Full Text] [Related]
10. High factor VIII (FVIII) levels in venous thromboembolism: role of unbound FVIII.
Schambeck CM; Grossmann R; Zonnur S; Berger M; Teuchert K; Spahn A; Walter U
Thromb Haemost; 2004 Jul; 92(1):42-6. PubMed ID: 15213843
[TBL] [Abstract][Full Text] [Related]
11. The D' domain of von Willebrand factor requires the presence of the D3 domain for optimal factor VIII binding.
Przeradzka MA; Meems H; van der Zwaan C; Ebberink EHTM; van den Biggelaar M; Mertens K; Meijer AB
Biochem J; 2018 Sep; 475(17):2819-2830. PubMed ID: 30111575
[TBL] [Abstract][Full Text] [Related]
12. A new method measuring the interaction between von Willebrand factor and coagulation factor VIII.
Karlman M; Holmström M; Wiman B
Thromb Res; 2011 Jan; 127(1):47-50. PubMed ID: 21094987
[TBL] [Abstract][Full Text] [Related]
13. Two novel mutations, Q1053H and C1060R, located in the D3 domain of von Willebrand factor, are responsible for decreased FVIII-binding capacity.
Hilbert L; Jorieux S; Proulle V; Favier R; Goudemand J; Parquet A; Meyer D; Fressinaud E; Mazurier C;
Br J Haematol; 2003 Feb; 120(4):627-32. PubMed ID: 12588349
[TBL] [Abstract][Full Text] [Related]
14. Identification of two point mutations in the von Willebrand factor gene of three families with the 'Normandy' variant of von Willebrand disease.
Gaucher C; Mercier B; Jorieux S; Oufkir D; Mazurier C
Br J Haematol; 1991 Aug; 78(4):506-14. PubMed ID: 1832934
[TBL] [Abstract][Full Text] [Related]
15. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
[TBL] [Abstract][Full Text] [Related]
16. Factor VIII-von Willebrand factor binding defects in autosomal recessive von Willebrand disease type Normandy and in mild hemophilia A. New insights into factor VIII-von Willebrand factor interactions.
Jacquemin M
Acta Haematol; 2009; 121(2-3):102-5. PubMed ID: 19506355
[TBL] [Abstract][Full Text] [Related]
17. Cerebral venous thrombosis and plasma concentrations of factor VIII and von Willebrand factor: a case control study.
Bugnicourt JM; Roussel B; Tramier B; Lamy C; Godefroy O
J Neurol Neurosurg Psychiatry; 2007 Jul; 78(7):699-701. PubMed ID: 17189302
[TBL] [Abstract][Full Text] [Related]
18. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
[TBL] [Abstract][Full Text] [Related]
19. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z
Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358
[TBL] [Abstract][Full Text] [Related]
20. von Willebrand factor and factor VIII as risk factors for arterial and venous thrombosis.
Martinelli I
Semin Hematol; 2005 Jan; 42(1):49-55. PubMed ID: 15662616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
